

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ALVOTECH USA INC. AND ALVOTECH HF,
Petitioner,

v.

REGENERON PHARMACEUTICALS, INC.,
Patent Owner.

PGR2025-00085
Patent 12,168,036

**DECLARATION OF PHILIP CHEN IN SUPPORT OF PETITIONER'S
MOTION FOR *PRO HAC VICE* ADMISSION**

I, Philip Chen, hereby declare to the following:

1. I am a member in good standing of the State Bar of Massachusetts and the District of Massachusetts.

2. I have not been suspended or disbarred from practice before any court or administrative body.

3. I have never had an application for admission to practice before any court or administrative body denied.

4. No sanction or contempt citation has been imposed against me by any court or administrative body.

5. I have read and will comply with the Office Patent Trial Practice Guide and the Board's Rules of Practice for Trials set forth in part 42 of Title 37 Code of Federal Regulations.

6. I will be subject to the USPTO Rules of Professional Conduct set forth in 37 C.F.R. §§ 11.101 *et seq.* and disciplinary jurisdiction under 37 C.F.R. § 11.19(a).

7. In the past three years, I have not applied for or received admission *pro hac vice*.

8. I am an experienced patent litigation attorney with over eight years of experience representing clients in cases involving biologics. I regularly litigate patent cases before the U.S. District Courts across the country, at the U.S.

International Trade Commission, as well as arguing or briefing cases in the U.S. Courts of Appeals, including at the Federal Circuit.

9. I am intimately familiar with the issues and subject matter presented in this above-captioned *post grant* review proceeding. For example, I have extensively reviewed the above identified patent, its prosecution history, the Petition for PGR (including the invalidity grounds therein, and the cited references), and all exhibits filed in this case.

10. My biography is attached hereto as Appendix A.

11. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Respectfully submitted,

Date: May 27, 2026

/Philip Chen/
PHILIP CHEN
Fish & Richardson P.C.
Email: Chen@fr.com

APPENDIX A



Philip K. Chen

Principal
Boston
617 521 7812
pchen@fr.com

Overview

Philip Chen advocates for clients in complex intellectual property litigation involving small-molecule pharmaceuticals, biologics, medical devices, and biotechnology, among other life sciences innovations.

Before beginning his career in law, Philip worked in translational research at a university. He now applies that same scientific curiosity and solutions-oriented mindset to devising and carrying out strong litigation strategies for his clients, whether in the life sciences or in other technology sectors, and his background also enables him to communicate fluently on technical issues with engineers, scientists, and experts.

Philip's notable achievements have included playing a key role in securing a win in a five-patent Hatch-Waxman trial for a pharmaceutical client. Additionally, he served on a trial team that secured an International Trade Commission (ITC) victory on appeal for a leading provider of robotic surgical systems. Philip has also worked on matters pertaining to copyright and trade secret litigation. From pre-suit diligence through litigation, he excels in case assessment, electronic document collection and production, fact and expert discovery, settlement strategy, trials, and appeals. While Philip focuses his practice in U.S. District Courts and has appeared in many across the country, he also has experience in handling ITC investigations and post-grant proceedings before the U.S. Patent and Trademark Office.

Outside of his work for IP clients, Philip dedicates significant time to his pro bono practice, in which he collaborates with Kids in Need of Defense and PAIR to represent clients in immigration and asylum matters.

Recognitions & awards

Pro Bono Honor Roll

Massachusetts Supreme Judicial Court 2019, 2021-2023

Insights

Blog | March 9, 2026

Biologics and Biosimilars Landscape 2025: IP, Policy, and Market Developments

Webinar | January 28, 2026

Biologics & Biosimilars 2025 Year in Review

Blog | February 24, 2025

Biology and Biosimilars Landscape 2024: IP, Policy, and Market Developments

Webinar | January 29, 2025

Biosimilars 2024 Year in Review

Blog | April 5, 2024

Biology and Biosimilars Landscape 2023: IP, Policy, and Market Developments

Webinar | January 30, 2024

Biosimilars 2023 Year in Review

Blog | January 17, 2023

Biosimilars 2022 Year in Review

Blog | January 11, 2022

Biosimilars 2021 Year in Review

Article | March 8, 2021

Regulatory And Legislative Actions Set The Tone For Biosimilars In 2021

Blog | February 4, 2021

Biosimilars 2020 Year in Review

News

January 5, 2026

Fish & Richardson Elevates Dynamic 2026 Class of New Principals

November 15, 2023

Thirteen Fish & Richardson Attorneys Named to Pro Bono Honor Roll by Massachusetts Supreme Judicial Court

October 27, 2022

Massachusetts Supreme Judicial Court Names 15 Fish Attorneys to Pro Bono Honor Roll

October 29, 2020

Massachusetts Supreme Judicial Court Names 20 Fish Attorneys to Pro Bono Honor Roll

January 16, 2019

Fish & Richardson Grows Firm With 14 Associates

Additional insights

Publications

- "Biosimilar Litigation Review: Anticompetitive Conduct Cases & Post-Grant Patent Challenges," *Biosimilar Development* (January 2020)
 - "Biosimilar Litigation Review: Ongoing BPCIA Federal Circuit Appeals Pending & Recently Decided," *Biosimilar Development* (January 2020)
 - "Biosimilar Litigation Review: Ongoing BPCIA Cases Settled Or Dismissed in 2019," *Biosimilar Development* (January 2020)
 - "Biosimilar Litigation Review: Ongoing BPCIA District Court Cases To Watch," *Biosimilar Development* (January 2020)
-

Services

Litigation

Patent Litigation

Trade Secret Litigation

IP Licensing, Transactions & Agreements

Post-Grant

Industries

Life Sciences

Medical Devices

Admissions

Massachusetts (2018)

Education

J.D. *cum laude*, Boston University School of Law (2018) Managing Editor, *Journal of Science & Technology Law*

A.B., Biology, Biochemistry, Washington University (2012)

Copyright © 2026 Fish & Richardson P.C.